Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Prostatic Neoplasms 3Leukemia 3Hematologic Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, B-Cell 2Lung Neoplasms 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sleep Initiation and Maintenance Disorders 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Nose Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1

Interventions

Rituximab 4blinatumomab 3Whole-Body Irradiation 3Cyclophosphamide 3fludarabine phosphate 2Mycophenolic Acid 2Melphalan 2Lenalidomide 2Clofarabine 2treosulfan 1thymoglobulin 1sabatolimab 1pembrolizumab 1peginterferon alfa-2a 1obinutuzumab 1midostaurin 1ixazomib 1fludarabine 1eribulin 1daratumumab 1acalabrutinib 1Trastuzumab 1Tacrolimus 1Sodium Chloride 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Pentostatin 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methotrexate 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Neoplasm, Residual × Electrocardiography × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡